Detalles de la búsqueda
1.
Vedolizumab for the Treatment of Chronic Pouchitis.
N Engl J Med
; 388(13): 1191-1200, 2023 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988594
2.
Gut virome in inflammatory bowel disease and beyond.
Gut
; 73(2): 350-360, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37949638
3.
IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
Gut
; 73(2): 282-297, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37884352
4.
The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease.
Neurobiol Dis
; 192: 106416, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38272141
5.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871574
6.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 385(14): 1280-1291, 2021 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587385
7.
Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions.
Clin Gastroenterol Hepatol
; 22(4): 896-898.e13, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743039
8.
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Clin Gastroenterol Hepatol
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38723981
9.
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Clin Gastroenterol Hepatol
; 2024 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38185396
10.
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis.
Gastroenterology
; 164(7): 1180-1188.e2, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871598
11.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38095692
12.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC Gastroenterol
; 24(1): 121, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539103
13.
Optimising surgical anastomosis in ileocolic resection for Crohn's disease with respect to recurrence and functionality: two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES).
BMC Surg
; 24(1): 71, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38408943
14.
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
Gut
; 72(9): 1642-1650, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37339849
15.
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
Gut
; 72(10): 1838-1847, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788014
16.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet
; 399(10342): 2200-2211, 2022 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691323
17.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
18.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
19.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644166
20.
Breaking Through the Therapeutic Ceiling: What Will It Take?
Gastroenterology
; 162(5): 1507-1511, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34995533